logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12758585 B1

PDFFull Text
Date of Patent:
Oct. 13, 2026

Filed:

May. 19, 2023

Vaccine comprising natural killer cells loaded with ligands of natural killer t cells and cancer antigens

Applicant:

Cellid Co., Ltd., Seoul, KR;

Inventors:

Chang-Yuil Kang, Seoul, KR;

Boyeong Song, Seoul, KR;

Insu Jeon, Seoul, KR;

Assignee:

CELLID CO., LTD., Seoul, KR;

Attorney:

Caesar Rivise, PC

Primary Examiner:

Maria Marvich

Int. Cl.
CPC ...
A61K 35/17 (2025.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 40/15 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 39/0012 (2013.01); A61K 39/12 (2013.01); A61K 40/15 (2025.01); A61P 35/00 (2018.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/53 (2013.01); A61K 2039/572 (2013.01); C12N 2710/10043 (2013.01); C12N 2710/20034 (2013.01);
Abstract

The present invention relates to an immunotherapeutic and preventive vaccine including natural killer cells loaded with ligands of natural killer T cells and cancer antigens, and more particularly, to an immunotherapeutic or preventive vaccine including natural killer cells loaded with alpha-galactosylceramide (α-GC), which is a natural killer T cell ligand and a type of glycolipid. The composition of the present invention can be used as an anticancer immunotherapeutic agent because natural killer cells are easier to obtain than dendritic cells, and immunization with natural killer cells loaded with ligands of natural killer T cells and antigens induces significant levels of cytotoxic T lymphocyte responses as well as therapeutic effects on malignant tumors.

Find Patent Forward Citations

Kang, Chang-Yuil. (2026). Vaccine comprising natural killer cells loaded with ligands of natural killer t cells and cancer antigens (U.S. Patent No. 12758585). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12758585

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…